Riding on early cancer detection frenzy, Freenome scores $270M to push liquid biopsy tech beyond colorectal cancer
Covid-19 and its manifold secondary effects have forced many biotech companies to adapt their clinical trials to the new normal. For Gabe Otte, it simply reinforced the importance of the tweaks Freenome was already planning with the pivotal study of its blood test for colorectal cancer.
While an average of 800,000 to a million Americans would get screened every month in the pre-pandemic times — around 5,000 to 7,000 of whom would be diagnosed with cancer and proceed to treatment — many would-be cancer patients are now not getting found.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.